The global mental health crisis continues escalating at an alarming pace. Depression and anxiety alone currently cost the world economy $1 trillion annually. Experts project this economic burden could swell to a staggering $6-16 trillion by 2030 as rates of mental illness proliferate across the globe.
Despite the pressing need, presently available mainstream treatments often have poor long-term outcomes and fail to deliver sufficient relief — especially for millions suffering from severe, chronic conditions like treatment-resistant depression, complex PTSD, and addiction.
However, an emerging renaissance in psychedelic-assisted therapy research shows immense promise for transforming outcomes where conventional protocols fall short.
A year of incredible progress, 2023 saw scientific breakthroughs abound. From revelations in epigenetic reprogramming and cellular biology to advancements in medical artificial intelligence technology, the longevity and anti-aging medicine movement forged forward at breakneck speed — and we did our best to keep pace.
So that you, valued members of our community of innovative health professionals, never missed a beat. Armed with the latest research takeaways, best practices, and breaking news, A4M Blog readers always stay ahead of the curve.
Stepping into 2024, we reflect on the monumental discoveries unlocked across the longevity landscape last year and the ones you found most captivating. We’ve gathered 2023’s most popular articles and hope you help us determine the A4M Reader’s Choice Award winner by casting your vote below! And the nominees are…
Complex, heterogenous, and often debilitating, depression is a multifaceted condition that affects millions of people worldwide. According to current statistics, one in five Americans will experience major depressive disorder (MDD) in their lifetime, and many will not find relief from current therapeutic approaches. While there is an ever-growing list of potential causes of MDD, recent research suggests that inflammation in the body may be a contributing factor to the development and severity of depression. And the latest clinical trial data suggest that targeting and treating inflammation as the root cause may help clinicians provide more precise, personalized care to patients struggling with depression and help them achieve lasting mental and physical wellness.